文献速递血栓与止血

直接口服抗凝药与华法林在癌症合并心房颤动患者中的比较有效性

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation.
PubMed 文献 · Blood Adv · 2018-01-01

在未开展直接口服抗凝药(DOAC)与华法林头对头随机试验的癌症合并心房颤动(AF)人群中,基于MarketScan数据库纳入16096例2010至2014年间启动抗凝且正在接受癌症治疗的患者,按年龄、性别、入组日期和药物启动日期匹配后比较。结果显示DOAC使用者出血率低于或类似于华法林,静脉血栓栓塞(VTE)发生率更低,缺血性卒中无差异。

要点

  • 与华法林相比,阿哌沙班使用者出血率更低(HR 0.37,95%CI 0.17-0.79)。
  • 与华法林相比,利伐沙班、达比加群和阿哌沙班使用者VTE发生率均更低。
  • 各抗凝药使用者之间缺血性卒中发生率无差异。

核心结论

  • 在癌症合并AF患者中,DOAC使用者出血和卒中发生率低于或类似于华法林使用者,且新发VTE发生率更低。

研究设计与样本

  • 利用MarketScan数据库识别16096例2010至2014年间启动口服抗凝且正在接受癌症治疗的AF患者(平均年龄74岁),按年龄、性别、入组日期和药物启动日期匹配抗凝药使用者,采用Cox回归估计抗凝药与研究终点的关联。

主要发现

  • 与华法林相比,利伐沙班使用者出血率为1.09(95%CI 0.79-1.39),达比加群为0.96(95%CI 0.72-1.27),阿哌沙班为0.37(95%CI 0.17-0.79)。
  • 与华法林相比,利伐沙班使用者VTE发生率为0.51(95%CI 0.41-0.63),达比加群为0.28(95%CI 0.21-0.38),阿哌沙班为0.14(95%CI 0.07-0.32)。
  • 各抗凝药使用者之间缺血性卒中发生率无差异。
  • 在DOAC头对头比较中,达比加群使用者VTE发生率低于利伐沙班使用者;阿哌沙班使用者VTE和严重出血发生率均低于利伐沙班使用者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Randomized clinical trials comparing direct oral anticoagulants (DOACs) to warfarin in cancer patients have not been performed. We evaluated the effectiveness and associated risk of DOACs vs warfarin, as well as comparisons of DOACs, in a large population of cancer patients with nonvalvular atrial fibrillation (AF). Using the MarketScan databases, we identified 16 096 AF patients (mean age, 74 years) initiating oral anticoagulant and being actively treated for cancer between 2010 and 2014. Anticoagulant users were matched by age, sex, enrollment date, and drug initiation date. Study end points were identified with diagnostic codes and included ischemic stroke, severe bleeding, other bleeding, and venous thromboembolism (VTE). Cox regression was used to estimate associations of anticoagulants with study end points. Compared with warfarin, rates of bleeding (hazard ratio [95% confidence interval]) were similar in rivaroxaban (1.09 [0.79, 1.39]) and dabigatran (0.96 [0.72, 1.27]) users, whereas apixaban users experienced lower rates (0.37 [0.17, 0.79]). Rates of ischemic stroke did not differ among anticoagulant users. Compared with warfarin, rate of VTE (hazard ratio [95% confidence interval]) was lower among rivaroxaban (0.51 [0.41, 0.63]), dabigatran (0.28 [0.21, 0.38]), and apixaban (0.14 [0.07, 0.32]) users. In head-to-head comparisons among DOACs, dabigatran users had lower rates of VTE than rivaroxaban users; apixaban users had lower rates of VTE and severe bleeding than rivaroxaban users. In this population of patients with AF and cancer, DOAC users experienced lower or similar rates of bleeding and stroke compared with warfarin users, and a lower rate of incident VTE.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Shah S, Norby FL, Datta YH, et al. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv. 2018. PMID: 29378726. doi:10.1182/bloodadvances.2017010694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。